A compound represented by the structure of formula (I(a(ii))): wherein R 1 is F, Cl, Br, I, OH, CF 3, OCH 3, CN, NO 2, -CH 2 CN, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched, or C 3 -C 8 cyclic haloalkyl, substituted or unsubstituted C 1 -C 5 linear or branched, or C 3 -C 8 cyclic alkoxy, C 1 -C 5 linear or branched haloalkoxy, NH-C -R 7, C 1 -C 5 linear or branched alkoxyalkyl; wherein R 7 is H, C 1 -C 5 substituted or unsubstituted linear or branched alkyl, C 1 -C 5 linear or branched alkoxy, C R, or S 2 R; wherein R is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched alkoxy, C 1 -C 5 linear or branched haloalkyl, R 6 -aryl, R 6 -N(alkyl) 2, R 6 -NH(alkyl), R 6 -NH(cycloalkyl), R 6 -NH(aryl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocyclic ring, R 6 -(substituted or unsubstituted heterocycle) or C -(alkyl); R 6 is [CH 2] p, [CH 2] pa -O-[CH 2] pb, or [CH 2] p -O; wherein p is 1, 2 or 3; and each pa and pb is independently an integer between 1 and 5; R 4 is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched, or C 3 -C 8 cyclic haloalkyl; R 6b is absent or O, C=O, [CH 2] p; R 8 is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched, or C 3 -C 8 cyclic haloalkyl; R 9 is substituted or unsubstituted saturated C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted saturated or unsaturated 3-8 membered heterocyclic ring or R 20, wherein R 20 is represented by the following structure: B ring is a single or fused 3-12 membered heterocyclic ring, C 3 -C 8 saturated or unsaturated cycloalkyl or a spiro ring system; X 6 is N; X 7 is CH or N; l and q are each independently an integer between 0 and 4; or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, N-oxide, or any combination thereof. R 1 is F, Cl, Br, I, OH, CF 3, OCH 3, CN, NO 2, -CH 2 CN, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched, or C 3 -C 8 cyclic haloalkyl, substituted or unsubstituted C 1 -C 5 linear or branched, or C 3 -C 8 cyclic alkoxy, C 1 -C 5 linear or branched haloalkoxy, NH-C -R 7, C 1 -C 5 linear or branched alkoxyalkyl; wherein R 7 is H, C 1 -C 5 substituted or unsubstituted linear or branched alkyl, C 1 -C 5 linear or branched alkoxy, C R, or S 2 R; wherein R is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched alkoxy, C 1 -C 5 linear or branched haloalkyl, R 6 -aryl, R 6 -N(alkyl) 2, R 6 -NH(alkyl), R 6 -NH(cycloalkyl), R 6 -NH(aryl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocyclic ring, R 6 -(substituted or unsubstituted heterocycle) or C -(alkyl); R 7 is H, C 1 -C 5 substituted or unsubstituted linear or branched alkyl, C 1 -C 5 linear or branched alkoxy, C R, or S 2 R; wherein R is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched alkoxy, C 1 -C 5 linear or branched haloalkyl, R 6 -aryl, R 6 -N(alkyl) 2, R 6 -NH(alkyl), R 6 -NH(cycloalkyl), R 6 -NH(aryl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocyclic ring, R 6 -(substituted or unsubstituted heterocycle) or C -(alkyl); R 6 is [CH 2] p, [CH 2] pa -O-[CH 2] pb, or [CH 2] p -O; wherein p is 1, 2 or 3; and each pa and pb is independently an integer between 1 and 5; p is 1, 2 or 3; and each pa and pb is independently an integer between 1 and 5; R 4 is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched, or C 3 -C 8 cyclic haloalkyl; R 6b is absent or O, C=O, [CH 2] p; R 8 is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched, or C 3 -C 8 cyclic haloalkyl; R 9 is substituted or unsubstituted saturated C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted saturated or unsaturated 3-8 membered heterocyclic ring or R 20, wherein R 20 is represented by the following structure: B ring is a single or fused 3-12 membered heterocyclic ring, C 3 -C 8 saturated or unsaturated cycloalkyl or a spiro ring system; R 6b is absent or O, C=O, [CH 2] p; R 8 is H, F, Cl, Br, I, OH, CF 3, CN, NO 2, C 1 -C 5 linear or branched, substituted or unsubstituted alkyl, C 1 -C 5 linear or branched, or C 3 -C 8 cyclic haloalkyl; R 9 is substituted or unsubstituted saturated C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 8 cycloalkenyl, substituted or unsubstituted saturated or unsaturated 3-8 membered heterocyclic ring or R 20, wherein R 20 is represented by the following structure: B ring is a single or fused 3-12 membered heterocyclic ring, C 3 -C 8 saturated or unsaturated cycloalkyl or a spiro ring system; X 6 is N; X 7 is CH or N; l and q are each independently an integer between 0 and 4; or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, N-oxide, or any combination thereof.